January 23, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, all ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

In the next step, the researchers want to develop new molecules based on digoxin that are even better at dissolving the CTC clusters.

Applied Therapeutics was not adhering to trial protocol and good clinical practices which, in turn, created an exceedingly severe risk that the trial data would be rejected by the U.S. Food and Drug ...

The move Tuesday followed a related executive order from Trump accusing former President Joe Biden of forcing “discrimination ...

The human gut microbiome—a dense and diverse ecosystem of microorganisms—plays a critical role in overall health. It aids in ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Certain tumor types do not remain at their point of origin but spread throughout the body and form metastases. This is ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...

Philip Morris Intl. expands into cannabis via Avicanna partnership, focusing on medical research and innovation: How this move aligns with its long-term strategy.

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x ...